Melanoma & Skin Cancer | Specialty

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

Dr. Atlas on the Current Treatment Paradigm in CSCC

August 14th 2020

Jennifer L. Atlas, MD, discusses the current cutaneous squamous cell carcinoma treatment paradigm.

Dr. Pavlick on the Safety Profile of Cemiplimab in CSCC

August 13th 2020

Anna C. Pavlick, DO, discusses common and uncommon adverse effects with cemiplimab in patients with cutaneous squamous cell carcinoma.

Dr. Milhem on Design of Phase 1b/2 Study With AST-008 in CSCC

August 13th 2020

Mohammed M. Milhem, MBBS, discusses the design of an open-label, multicenter phase 1b/2 dose escalation/expansion study with AST-008 in combination with a PD-1 inhibitor, such as pembrolizumab or cemiplimab, in Merkel cell carcinoma and cutaneous squamous cell carcinoma.

Novel Triplet Emerges as a Promising Option in BRAF-Mutant Melanoma

August 13th 2020

Georgina V. Long, BSc, PhD, MBBS, FRACP, discusses the safety profile of the combination of spartalizumab, dabrafenib, and trametinib, the clinical implications of the biomarker data observed from this trial, and other emerging combinations on the horizon.

Dr. Blank on Personalizing Neoadjuvant Therapy in Stage III Macroscopic Melanoma

August 12th 2020

Christian U. Blank, MD, PhD, discusses ongoing research efforts to personalize neoadjuvant therapy in stage III macroscopic melanoma.

AST-008 Plus PD-1 Blockade Shows Early Synergy in Merkel Cell Carcinoma, CSCC

August 12th 2020

Mohammed M. Milhem, MBBS, discusses the promise of the AST-008 combination in patients with Merkel cell carcinoma and CSCC who do not achieve a response with PD-1 inhibitors alone.

Breaking Down the Benefit of Neoadjuvant Nivolumab/Ipilimumab in Stage III Macroscopic Melanoma

August 12th 2020

Christian U. Blank, MD, PhD, discusses the promise of neoadjuvant ipilimumab/nivolumab and research efforts examining interferon-gamma signature and tumor mutational burden as potential predictors of response.

Khushalani on Building Upon the Benefit Achieved With Cemiplimab in CSCC

August 11th 2020

Nikhil Khushalani, MD, discusses cemiplimab-rwlc, which has become the preferred agent for the frontline treatment of patients with metastatic or locally advanced cutaneous squamous cell carcinoma.

Recent Advances in Melanoma

August 10th 2020

Grace Cherry, RN, MSN, NP, discusses recent advances in melanoma.

Dr. Atlas on the Rationale for Cemiplimab in Locally Advanced CSCC

August 7th 2020

Jennifer L. Atlas, MD, discusses the rationale for using cemiplimab-rwlc as a first intervention for patients with locally advanced cutaneous squamous cell carcinoma.

Longer Follow-Up Data Confirms Cemiplimab’s Utility in CSCC, Though Challenges Remain

August 7th 2020

Anna C. Pavlick, DO, discusses the benefit of cemiplimab for patients with cutaneous squamous cell carcinoma (CSCC), the impact of these longer follow-up data, rare, but notable, toxicities that can arise with the agent, and ongoing research efforts aimed at increasing responses to immunotherapy in the CSCC space.

Dr. Blank on Predictive Biomarkers in Macroscopic Stage III Melanoma

August 5th 2020

Christian U. Blank, MD, PhD, discusses the future of baseline biomarkers in macroscopic stage 3 melanoma.

FDA Approves Atezolizumab Plus Cobimetinib/Vemurafenib in BRAF+ Advanced Melanoma

July 30th 2020

The FDA has approved atezolizumab (Tecentriq) in combination with cobimetinib (Cotellic) and vemurafenib (Zelboraf) in the treatment of patients with BRAF V600 mutation–positive advanced melanoma.

Melanoma Experts Make Sense of ASCO 2020 Data and Advise on Clinical Implications

July 30th 2020

As new data emerge in the melanoma treatment paradigm, new questions have come to light regarding neoadjuvant/adjuvant strategies, reduced dosing for immunotherapy combinations, and approaches following progression on, or resistance to, PD-1 inhibition.

Dr. Glitza Olivia on the Prognosis of Melanoma Brain Metastases

July 28th 2020

Isabella C. Glitza Oliva, MD, PhD, MS, discusses the prognosis of patients with melanoma brain and/or central nervous system metastases.

Pembrolizumab Provides Long-Term Benefit in Melanoma, Regardless of BRAF+ Status or Prior Targeted Therapy

July 27th 2020

Pembrolizumab was found to prolong survival in patients with advanced melanoma, regardless of BRAF V600E/K mutation status or prior administration of a BRAF inhibitor with or without a MEK inhibitor.

Dr. Chandra on Unanswered Questions With Targeted Therapy in Melanoma

July 24th 2020

Sunandana Chandra, MD, MS, discusses unanswered questions regarding the utility of targeted therapy in melanoma.

Dr. Shapiro on the Utility of Complete Lymph Node Dissection in Melanoma

July 23rd 2020

Richard L. Shapiro, MD, discusses the utility of complete lymph node dissection in melanoma.

Dr. Chandra on the Incidence of Targetable Mutations in Melanoma

July 21st 2020

Sunandana Chandra, MD, MS, discusses the incidence of targetable mutations in melanoma.

Dr. Luke on Future Research With T-Cell Therapy in Melanoma

July 15th 2020

Jason J. Luke, MD, FACP, discusses the future of T-cell therapy in melanoma.